Application of schisandrin B in preparation of drugs used for preventing colitis or colorectal carcinomas

A technology of Schisandra B and colitis, which is applied in the directions of drug combination, antitumor drug, active ingredient of heterocyclic compounds, etc., can solve the problems such as no literature report and patent disclosure, and achieves the reduction of the production of inflammatory factors. Prospects for application and good druggability

Active Publication Date: 2015-08-12
ZHEJIANG DINGHUI PHARM
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Schizandrin B can cause apoptosis of human cervical cancer cells, and inhibit epithelial-mesenchymal transition when cancer cells develop locally, slow down cancer invasion and metastasis, and provide the possibility of its application in cancer treatment, but There are no literature reports and patent publications showing that Schizandrin B has any application prospects in the preparation of drugs for the prevention and treatment of colitis or colon cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of schisandrin B in preparation of drugs used for preventing colitis or colorectal carcinomas
  • Application of schisandrin B in preparation of drugs used for preventing colitis or colorectal carcinomas
  • Application of schisandrin B in preparation of drugs used for preventing colitis or colorectal carcinomas

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1: Schizandrin B reduces the occurrence of colonic tumors associated with colitis

[0037] (1) Experimental materials:

[0038] Experimental reagent: Schizandrin B (purity ≥ 95%, here is the mass percentage), with 5mg / ml CMC-Na solution respectively made into two concentrations of 1.5mg / ml and 0.75mg / ml, carried out by 20ml / kg mouse body weight Administration; Carboxymethylcellulose sodium (CMC-Na) was purchased from Sinopharm Group, and was made into a 5mg / ml solution with double distilled water; azoxymethane (AOM) was purchased from Sigma Company, and was made into a 0.5mg / ml solution with normal saline The AOM working solution of ml was administered according to 20 ml / kg mouse body weight; dextran sodium sulfate (DSS) was purchased from MP Biomedicals, and a 25 mg / ml DSS solution was prepared with physiological saline.

[0039] Experimental animals: C57 male mice, 8 weeks old, weighing 18-20 g, purchased from Beijing Weitong Lihua.

[0040] (2) Experimental...

Embodiment 2

[0056] Example 2: Schizandrin B reduces inflammatory conditions in colitis-associated colon cancer

[0057] (1) Experimental materials:

[0058] Experimental reagents: mTNF-α (EM008), mIL-1β (EM001), mIL-6 (EM004), mIL-10 (EM005), mTGF-β1 (EM010) ELISA kits were purchased from Shanghai Yikesai Biological Company; Primers for mTNF-α, mIL-1β, mIL-6, mIL-10, mTGF-β1 were set at GenScript, Nanjing; Takara, PrimeScriptTM RT reagent Kit with gDNA Eraser (Perfect Real Time), Code No.RR047A; Takara, Premix Ex Taq TM II (Tli RNaseH Plus), Code No.RR820A; BCA protein quantification kit.

[0059] Experimental equipment: Nucleic acid quantitative instrument (Eppendorf), constant temperature water bath, ordinary PCR instrument, ABI Step One Plus real-time quantitative PCR instrument, automatic microplate reader, desktop high-speed refrigerated centrifuge, biochemical incubator.

[0060] (2) Experimental method:

[0061] 1) Blood was collected from the orbital venous plexus of the AOM / ...

Embodiment 3

[0095] Example 3: Schizandrin B reduces the occurrence of colitis

[0096] (1) Experimental materials and experimental equipment are the same as in Example 1.

[0097] (2) Experimental method

[0098] Thirty-two C57 male mice were randomly divided into 4 groups, 8 in each group: solvent control group, DSS model group, DSS+Sch B high-dose group, DSS+Sch B low-dose group. Solvent control group: in the first week of the experiment, the mice were given 5 mg / ml CMC-Na solution by intragastric administration every day, and began to drink water freely for 8 days on the 8th day; DSS model group: in the first week of the experiment, the mice were given 5 mg / ml by intragastric administration every day CMC-Na solution, given 25mg / ml DSS solution on the 8th day, and then freely drinking water for 8 days; DSS+Sch B high / low dose group: In the first week of the experiment, mice were given Sch B (30mg / kg or 15mg / kg mouse body weight) solution, on the 8th day, each group began to give 25mg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of schisandrin B in preparation of drugs used for preventing colitis or colorectal carcinomas. The usage amount of schisandrin B is 15 to 30 mg per kg of body weight. Schisandrin B can effectively prevent colitis and colorectal carcinomas related to colitis, so schisandrin B has clinical application prospect; schisandrin B has low toxicity and small side-effect, can reduce generation of inflammatory factors and has good druggability; thus, schisandrin B has good application prospects in clinical prevention and treatment.

Description

(1) Technical field [0001] The invention relates to the application of schisandrin B in the preparation of medicines for treating and preventing colitis or colon cancer. (2) Background technology [0002] Colorectal cancer (CRC) is one of the common malignant tumors. Its incidence rate of malignant tumors has risen to the third place in the world, and its mortality rate ranks second among malignant tumors. The mortality rate of colon cancer in my country ranks fifth among malignant tumors. , seriously endangering human health. Colon cancer originates from intestinal epithelial cells, through a series of complex genetic and epigenetic changes, accumulated over a long period of time, and finally undergoes malignant transformation of cells, forming a specific type of cancer. When colon cancer develops, its clinical treatment is also very difficult, mainly because colon cancer has no clear cause, so there is still no effective method to completely cure colon cancer. During the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/36A61P1/00A61P35/00
Inventor 杨勇张敏何莉华胡开永
Owner ZHEJIANG DINGHUI PHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap